NCT00803374View on ClinicalTrials.gov

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

January 31, 2013

Conditions
Melanoma
Interventions
DRUG

AntiCD137

Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

DRUG

AntiCD137

Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

DRUG

AntiCD137

Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

DRUG

AntiCD137

Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

DRUG

AntiCD137

Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response

DRUG

Ipilimumab

Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response

Trial Locations (7)

10021

Local Institution, New York

33612

Local Institution, Tampa

90025

Local Institution, Los Angeles

06520

Local Institution, New Haven

02114

Local Institution, Boston

02115

Local Institution, Boston

02215

Local Institution, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY